A glyco-engineered anti-HER2 monoclonal antibody (TrasGEX) induces a long-lasting remission in a patient with HER2 overexpressing metastatic colorectal cancer after failure of all available treatment options

Detalles Bibliográficos
Autores principales: Eisner, Florian, Pichler, Martin, Goletz, Steffen, Stoeger, Herbert, Samonigg, Hellmut
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2015
Materias:
PostScript
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717383/
https://www.ncbi.nlm.nih.gov/pubmed/26386048
http://dx.doi.org/10.1136/jclinpath-2015-202996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4717383/
https://www.ncbi.nlm.nih.gov/pubmed/26386048
http://dx.doi.org/10.1136/jclinpath-2015-202996

Ejemplares similares